Pre-made Nirsevimab benchmark antibody ( Whole mAb, anti-RSV therapeutic antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-ab-379

Pre-Made Nirsevimab biosimilar, Whole Mab: Anti-RSV therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Nirsevimab is a passive immunisation, designed to provide RSV protection to all infants, whereby an antibody is given directly to an infant to help prevent RSV, unlike active immunisation, where a person's immune system is activated to prevent or fight infection through a vaccine.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package List Price(In USD) Discount off Discount Price
GMP-Bios-ab-379-1mg 1mg 3090 Inquiry Inquiry

Size: 1mg | 10mg | 100mg



Description

Products Name (INN Index) Pre-Made Nirsevimab biosimilar, Whole Mab: Anti-RSV therapeutic antibody
INN Name Nirsevimab
TargetRSV
FormatWhole mAb
DerivationHuman
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-III
Est. StatusActive
100% SI Structure5udc:HL:BC:EG
99% SI StructureNone
95-98% SI Structure4jha:HL/4jhw:HL
Year Proposed2018
Year Recommended2019
CompaniesAIMM Therapeutics;MedImmune
Conditions Approvedna
Conditions ActiveRespiratory syncytial virus infections
Conditions Discontinuedna
Development Techna


Validation Data


SDS-PAGE and HPLC results of GMP-Bios-ab-379

Figure. >95% purity by SDS-PAGE under reduced conditions, >95% purity by SEC-HPLC test

Click to get more Data / Case study about the product.